Protagonist Therapeutics (PTGX) Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. HOOD
8. DFTX
9. USO
10. RGNX

Go back to Protagonist Therapeutics (PTGX) Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
(NASDAQ: PTGX) Delayed: 114.77 +1.91 (1.69%)
Previous Close $112.86    52 Week High $24.52 
Open $113.24    52 Week Low $10.02 
Day High $116.25    P/E N/A 
Day Low $113.24    EPS $0.00 
Volume 707,683